

BEBPA 2026 Biomarker Conference

23-24 June 2026

Virtual Conference

Audience Survey




Day 1 - Intro Audience Surveys

2026 Biomarker Assay Conference
Tuesday, 23 June


Introduction: Laureen Little
President, BEBPA




i.1 What is your primary role in biomarker assay work?




i.2 How many years have you worked with biomarker assays?




i.3 What type of organization do you represent?



i.4 Which platform do you use most for biomarker assays?



i.5 Has any regulatory authority raised questions about any of your biomarker assays?




Day 1 - Audience Surveys

2026 Biomarker Assay Conference
Tuesday, 23 June


Session Chair: Anton Stetsenko
BioQual Consulting




1.1 When does your organization typically begin biomarker assay development?




1.2 Which characteristics are the most important for a successful biomarker assay?




1.3 Which category best describes the statistical methods you use most often for biomarker analysis?




1.4 How does Immunogenicity Risk Assessment (IRA) help plan immunogenicity evaluations in clinical studies?




1.5 Which statement best reflects your organization's approach to immunogenicity assessment?




1.6 Which category is least relevant as a major immunogenicity risk factor?



1.7 Which statement best reflects current thinking about NAb assessment?



1.8 Which factor most contributes to elevated immunogenicity risk?




Day 2 - Audience Surveys

2026 Biomarker Assay Conference
Wednesday, 24 June


Session Chair: Anton Stetsenko
BioQual Consulting




2.1 What is your biggest challenge in biomarker assay validation?




2.2 Which pre-analytical sample specific factors causes the most issues?




2.3 What is the most common cause of failure in your assays?



2.4 Do you routinely use multiplex assays?




2.5 How often does sample quality impact assay success?



2.6 How do you deal with discrete data when comparing to assays with continuous data?

nonparametric tests break into categories
 difficult consult my statistician
positive vs negative
determine cut points
 concordance

2.6 How do you deal with discrete data when comparing to assays with continuous data?





Thank you!!